Equity · Healthcare
TEVJF
OTC MARKETS OTCPKTeva Pharmaceutical Industries (TEVJF)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Revenue, year to Dec 2025
- 17.3B USD
- EPS, diluted, year to Dec 2025
- 1.21 USD
Which funds hold Teva Pharmaceutical Industries (TEVJF)?
12 of the 45 institutional funds we track reported a Teva Pharmaceutical Industries position for the quarter ended 30 Sep 2026 — a combined 584.3M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Glenview Capital Management | New position | 7,566,877 | 299.6M USD | |
| Marshall Wace | New position | 2,782,756 | 110.2M USD | |
| Millennium Management | New position | 1,465,716 | 58.0M USD | |
| Bridgewater Associates | New position | 982,873 | 38.9M USD | |
| Citadel Advisors | New position | 766,167 | 30.3M USD | |
| Tudor Investment Corp | New position | 440,000 | 17.4M USD | |
| D. E. Shaw & Co. | New position | 205,840 | 8.2M USD | |
| Two Sigma Investments | New position | 193,287 | 7.7M USD | |
| AQR Capital Management | New position | 144,634 | 5.7M USD | |
| Man Group | New position | 72,211 | 2.9M USD |
Showing the 10 largest of 12 reported positions. The figures above count all of them.
What has been filed or recorded for Teva Pharmaceutical Industries (TEVJF)?
The filings we hold for Teva Pharmaceutical Industries, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Jun 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.49 USD | |
| 30 Jun 2026 | Financials | Total assets | 39.9B USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 7.8B USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS 0.31 USD | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS 1.21 USD | Revenue $1.50B |
| 31 Dec 2025 | Financials | Revenue | 17.3B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 1.4B USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | 1.21 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS 0.37 USD | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS 0.24 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS 0.18 USD | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.45 USD | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.39 USD |
What do people ask about Teva Pharmaceutical Industries (TEVJF)?
What is Teva Pharmaceutical Industries’ revenue?17.3B
Teva Pharmaceutical Industries reported revenue of 17.3B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Which funds own Teva Pharmaceutical Industries?12 of 45
12 of the 45 funds we track reported a Teva Pharmaceutical Industries position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Glenview Capital Management, Marshall Wace and Millennium Management. See Funds
When did Teva Pharmaceutical Industries last report earnings?−0.49
Teva Pharmaceutical Industries last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.49 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- Company websiteAbout text: the company's own website, summarised in our own words